Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right

Cipla is planning an ambitious growth trajectory, aiming to propel its US business “towards a $1bn generic enterprise” and develop a strong specialty franchise focused on its traditional stronghold, the respiratory segment, and the CNS space.